Espace privéDéconnexion
Email 
Mot de passe 

principales publications 2016

1.Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open. 2016 Jun 24;6(6):e010696.

2.Anota A., Cottone F., Barbieri A., Bascoul-Mollevi C., Efficace F. and Bonnetain F. Longitudinal analysis of the health-related quality of life in oncology integrating the occurrence of the response shift effect. Italian Journal of Applied Statistics: Statistica Applicata - Vol. 27, num.1; 2016

3.Anota A, Mariet AS, Maingon P, Joly F, Bosset JF, Guizard AV, Bittard H, Velten M, Mercier M. Cross-cultural adaptation and validation of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life of prostate cancer patients. Health Qual Life Outcomes. 2016 Dec 6;14(1):168.

4.Barbieri A, Anota A, Conroy T, Gourgou-Bourgade S, Juzyna B, Bonnetain F, Lavergne C, Bascoul-Mollevi C. Applying longitudinal model from Item Response Theory to assess the Health-Related Quality of Life in PRODIGE 4 / ACCORD 11 randomized trial. Med Decis Making. 2016 Jul;36(5):615-28.

5.Baumstarck K, Leroy T, Hamidou Z, Tabouret E, Farina P, Barrié M, Campello C, Petrirena G, Chinot O, Auquier P. Coping with a newly diagnosed high-grade glioma: patient-caregiver dyad effects on quality of life.J Neurooncol. 2016 Aug;129(1):155-64.

6.Bayti T, Panouilleres M, Tropet Y, Bonnetain F, Pauchot J. [Fat grafting in breast reconstruction. Retrospective study of satisfaction and quality of life about 68 patients]. Ann Chir Plast Esthet. 2016 Jun;61(3):190-9.

7.Bonnetain F, Efficace F, Fiteni F,Anota A. Reply to B. Kurland et al. J Clin Oncol. 2016 Dec 20;34(36):4450-4451.

8.Bonnetain F., Fiteni F., Efficace F., Anota A. Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. J Clin Oncol. 2016 Jun 1;34(16):1953-6.

9.Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med. 2016 Apr;5(4):676-83.

10.Chu WO, Dialla PO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, Arveux P, Dabakuyo-Yonli TS. Determinants of quality of life among long-term breast cancer survivors. Qual Life Res. 2016 Feb 25.

11.Diouf M, Filleron T, Pointet AL, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Fein F, Dubreuil O, Landi B, Zaanan A, Taieb J, Bonnetain F. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Qual Life Res. 2016 Jul;25(7):1713-23.

12.Fiteni F,Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. Eur Respir J. 2016 Sep;48(3):861-72.

13.Fiteni F., Anota A., Westeel V., Bonnetain F. Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a systematic review. BMC Cancer. 2016 Feb 18;16(1):122.

14.Fiteni F, Bonnetain F. Surrogate end points for overall survival in breast cancer trials: A review. Breast. 2016 Oct;29:44-8. Epub 2016 Jul 9.

15.Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. Eur J Cancer. 2016 Jan;52:120-8.

16.Fournier E, Jooste V, Woronoff AS, Quipourt V, Bouvier AM, Mercier M. Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study. Dig Liver Dis. 2016 Jan;48(1):87-93. Epub 2015 Sep 28

17.Hamidou Z, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol ML, de Gramont A, Bonnetain F. Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. PLoS One. 2016 Jun 16;11(6):e0157067. eCollection 2016.

18.Kerleau C, Guizard AV, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, Joly F; French Network of Cancer Registries (FRANCIM). Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer. 2016 Aug;63:143-53.

19.Lazzarotto S, Baumstarck K, Loundou A, Hamidou Z, Aghababian V, Leroy T, Auquier P. Age-related hearing loss in individuals and their caregivers: effects of coping on the quality of life among the dyads. Patient Prefer Adherence. 2016 Nov 7;10:2279-2287.

20.Opsomer MA,Anota A, Noblot-Rossignol M, Bonnetain F, Pernot C, Chretien ML, Legouge C, Caillot D, Boulin M.Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies. Ann Pharm Fr. 2016 Nov;74(6):439-447.

21.Ousmen, T. Conroy, F. Guillemin, M. Velten, D. Jolly, M. Mercier, S. Causeret, J. Cuisenier, O. Graesslin, Z. Hamidou, F. Bonnetain, A. Anota. Impact of the occurrence of the response shift effect on the determination of the minimal clinically important difference in a health-related quality of life score over time Health Qual Life Outcomes. 2016 Dec 3;14(1):167.

22.Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A,Bonnetain F. Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Med. 2016 Aug;5(8):1753-64.

23.Pozet A, Lejeune C, Bonnet M, Dabakuyo S, Dion M, Fagnoni P, Gaimard M, Imbert G, Nerich V, Foubert A, Chotard M, Bonin M,Anota A, Bonnetain F. Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trial. Trials. 2016 Nov 3;17(1):531.

24.Vernerey D, Anota A, Vandel P, Paget-Bailly S, Dion M, Bailly V, Bonin M, Pozet A, Foubert A, Benetkiewicz M, Manckoundia P, Bonnetain F. Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty. BMC Geriatr. 2016 Nov 17;16(1):187. Erratum in: BMC Geriatr. 2016 Dec 9;16(1):212.


Nos partenaires

https://www.ligue-cancer.net/